Fig. 8From: HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanismMolecular mechanism graph. HDAC inhibitor ITF2357 elevates the expression of miR-130a-3p by inhibiting HDAC2, which inhibits Rad51, thereby reducing the resistance of mut-KRAS NSCLC to PemBack to article page